Related Experiment Videos
[A refractory case of relapsing polychondritis]
1First Department of Internal Medicine, Tokyo Medical & Dental University.
Summary
Salazosulfapyridine (SASP) induced complete remission in a relapsing polychondritis (RPC) patient refractory to multiple treatments. This finding suggests SASP may be a valuable therapeutic option for severe, treatment-resistant RPC cases.
Area of Science:
- Rheumatology
- Immunology
Background:
- Relapsing polychondritis (RPC) is a rare, systemic autoimmune disease characterized by progressive cartilage destruction.
- Management of refractory RPC often requires aggressive immunosuppressive therapies with significant side effects.
Observation:
- A 15-year-old female diagnosed with RPC presented with severe chondritis, ocular inflammation, and vestibular dysfunction.
- The patient was refractory to various treatments including corticosteroids, cyclophosphamide, methotrexate, intravenous immunoglobulin, and cyclosporine A.
Findings:
- Salazosulfapyridine (SASP), introduced in combination with oral corticosteroids and cyclosporine A, achieved complete remission.
- SASP demonstrated a steroid-sparing effect, allowing for reduced corticosteroid dosage.
Implications:
- SASP may represent a novel and effective therapeutic strategy for refractory relapsing polychondritis.
- This case highlights the potential utility of SASP in managing severe autoimmune cartilage disorders.